Moderna has been granted a patent for a nucleic acid vaccine that includes RNA polynucleotides encoding varicella zoster virus antigens. The vaccine composition comprises mRNA encoding VZV glycoproteins and a lipid nanoparticle. This innovative vaccine technology could potentially revolutionize the field of immunization. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Moderna Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of February 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Vaccine composition for varicella zoster virus

Source: United States Patent and Trademark Office (USPTO). Credit: Moderna Inc

A recently granted patent (Publication Number: US11918644B2) discloses a vaccine composition designed to target the varicella zoster virus (VZV) by utilizing a messenger ribonucleic acid (mRNA) encoding specific glycoproteins. The composition includes a lipid nanoparticle with precise proportions of ionizable cationic lipid, neutral lipid, cholesterol, and polyethylene glycol (PEG)-modified lipid. The mRNA in the vaccine composition can be chemically modified to enhance its efficacy, with options such as pseudouridine, N1-methylpseudouridine, and other modifications listed in the claims.

Furthermore, the patent details variations in the lipid nanoparticle composition, specifying different percentages of cationic lipid, neutral lipid, cholesterol, and PEG-modified lipid. The specific amino acid sequences of the VZV glycoproteins targeted by the vaccine are also highlighted, including mutations like Y569A in the VZV gE protein. The patent emphasizes the use of chemically modified mRNA, such as N1-methylpseudouridine, to encode the VZV glycoproteins, enhancing the vaccine's potential effectiveness. Overall, the patent provides a detailed framework for a vaccine composition targeting VZV, utilizing innovative mRNA and lipid nanoparticle technology for improved immunization strategies.

To know more about GlobalData’s detailed insights on Moderna, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies